VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

CX3CR1 has been identified as a highly attractive target for several therapeutic interventions. Despite this potential, no potent antagonists, either small molecule or monoclonal antibody, have been identified. Here we describe the lead finding and engineering approach that lead to the identificatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Low, Sarah, Wu, Haixia, Jerath, Kavita, Tibolla, Annette, Fogal, Birgit, Conrad, Rebecca, MacDougall, Margit, Kerr, Steven, Berger, Valentina, Dave, Rajvee, Villalona, Jorge, Pantages, Lynn, Ahlberg, Jennifer, Li, Hua, Van Hoorick, Diane, Ververken, Cedric, Broadwater, John, Waterman, Alisa, Singh, Sanjaya, Kroe-Barrett, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973309/
https://www.ncbi.nlm.nih.gov/pubmed/31924119
http://dx.doi.org/10.1080/19420862.2019.1709322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973309/
https://www.ncbi.nlm.nih.gov/pubmed/31924119
http://dx.doi.org/10.1080/19420862.2019.1709322

Ejemplares similares